Skip to Content

Join the 'Alogliptin / pioglitazone' group to help and get support from people like you.

Alogliptin / pioglitazone News

Intensive Type 2 Diabetes Treatment Can Extend Survival: Study

Posted 8 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – Intensive management of type 2 diabetes can make a difference in how long and how well you live, even if you don't start until middle age, researchers report. People who were already at risk of type 2 diabetes complications were randomly selected to continue with their normal treatment or to be placed in an aggressive and multipronged treatment group. Two decades after the study began, the researchers found that people in the aggressive treatment group lived almost eight years longer. Not only that, they lived better – their risk of heart disease, kidney disease and blindness all dropped. The only complication that didn't seem to improve was nerve damage caused by diabetes. "Early, intensified intervention in type 2 diabetes patients with microalbuminuria with both target-driven pharmacological (medication) and behavioral actions increased life span. And, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Bydureon, Janumet, Byetta, Saxenda, Glyburide, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

Intensive Blood Sugar Control May Be Too Much for Some With Type 2 Diabetes

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – Intensive treatment of blood sugar levels in some people with type 2 diabetes may cause serious complications, new research suggests. "In this study, we found that, particularly among older patients and patients with serious chronic conditions, intensive treatment nearly doubled the risk of severe hypoglycemia requiring medical attention, including hospitalization," said lead author Dr. Rozalina McCoy. She is an endocrinologist at the Mayo Clinic in Rochester, Minn. Hypoglycemia (low blood sugar) is a serious potential complication of diabetes treatment. The researchers said it can worsen quality of life and has been linked with cardiovascular events, dementia and death. The researchers reviewed information from more than 31,500 American adults. All had stable and controlled type 2 diabetes. None was taking insulin. None had a prior history of severe ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Dementia, Glucophage, Novolog, Glipizide, Humalog, Hypoglycemia, Janumet, Glyburide, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride, Amaryl, Novolin R, Pioglitazone

FDA Medwatch Alert: Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication - Risk of Heart Failure

Posted 5 Apr 2016 by Drugs.com

ISSUE: An FDA safety review has found that type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease. As a result, FDA is adding new warnings to the drug labels about this safety issue. Medicines containing saxagliptin and alogliptin include: Onglyza (saxagliptin) Kombiglyze XR (saxagliptin and metformin extended release) Nesina (alogliptin) Kazano (alogliptin and metformin) Oseni (alogliptin and pioglitazone) This Communication is an update to the 02/11/2014 FDA Drug Safety Communication. BACKGROUND: Saxagliptin and alogliptin are part of the class of dipeptidyl peptidase-4 (DPP-4) inhibitor drugs, which are used with diet and exercise to lower blood sugar in adults with type 2 diabetes. FDA evaluated two large clinical trials conducted in patients with heart disease. These ... Read more

Related support groups: Diabetes, Type 2, Onglyza, Oseni, Alogliptin, Nesina, Saxagliptin, Kombiglyze XR, Alogliptin/pioglitazone, Kazano, Alogliptin/metformin, Metformin/saxagliptin

FDA: 2 Diabetes Drugs May Be Linked to Heart Failure Risk

Posted 5 Apr 2016 by Drugs.com

TUESDAY, April 5, 2016 – Diabetes drugs containing saxagliptin and alogliptin may raise the risk of heart failure, particularly in patients with heart or kidney disease, U.S. health officials warned Tuesday. Drugs containing these ingredients are Onglyza (saxagliptin), Kombiglyze XR (saxagliptin and metformin extended release), Nesina (alogliptin), Kazano (alogliptin and metformin) and Oseni (alogliptin and pioglitazone), the U.S. Food and Drug Administration said. People with type 2 diabetes who use these drugs should not stop taking them without consulting with their doctor, the FDA said. The agency added that patients on these drugs should contact their doctor if they develop signs and symptoms of heart failure, including: Unusual shortness of breath during daily activities. Difficulty breathing when lying down. Tiredness, weakness or fatigue. Weight gain with swelling of the ... Read more

Related support groups: Diabetes, Type 2, Heart Failure, Congestive Heart Failure, Onglyza, Left Ventricular Dysfunction, Diabetes Mellitus, Oseni, Alogliptin, Nesina, Saxagliptin, Kombiglyze XR, Alogliptin/pioglitazone, Kazano, Alogliptin/metformin, Metformin/saxagliptin

Cost of Insulin Rises Threefold in Just a Decade: Study

Posted 5 Apr 2016 by Drugs.com

TUESDAY, April 5, 2016 – Americans with diabetes who rely on insulin to keep their blood sugar levels in check are facing sticker shock: A new study finds the price of insulin has tripled in only 10 years. Moreover, since 2010, per-person spending on insulin in the United States was more than spending on all other diabetes drugs, the study found. "The cost of insulin has risen rapidly over the last few years," said study senior author Philip Clarke, a professor of health economics at the University of Melbourne in Australia. Clarke added there should be an assessment to see whether this price hike is justifiable in terms of improved clinical outcomes. One reason for the price climb, he said, is a switch from human insulins to analog insulins, which cost more but may offer additional benefits. Also, doctors are more apt to prescribe insulin for people with type 2 diabetes now, Clarke ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Diabetes, Type 1, Januvia, Diabetic Neuropathy, Glucophage, Novolog, Glipizide, Humalog, Insulin Resistance, Bydureon, Byetta, Janumet, Diabetic Nerve Damage, Glyburide, Saxenda, Lantus Solostar

More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a Bit

Posted 31 Mar 2016 by Drugs.com

WEDNESDAY, March 30, 2016 – More evidence linking the diabetes drug Actos to an increased risk of bladder cancer has surfaced in a new study that also finds the risk rises with increased use. Actos (pioglitazone) appears to increase risk of bladder cancer by 63 percent, Canadian researchers say. The findings, published March 30 in The BMJ, stem from an analysis of nearly 146,000 patients treated between 2000 and 2013. The data also showed that bladder cancer risk increases if Actos is used for more than two years, or if someone takes more than 28,000 milligrams over the course of their lives. The overall risk is small, however. Still, "the more you accumulate the drug into your system, the higher the risk," said senior researcher Laurent Azoulay, an associate professor of oncology at McGill University in Montreal. Azoulay and his colleagues did not find a similar link between bladder ... Read more

Related support groups: Diabetes, Type 2, Insulin Resistance, Actos, Pre-Diabetes, Pioglitazone, Diabetes Mellitus, Avandia, Bladder Cancer, ActoPlus Met, Avandamet, Abnormal Glucose Tolerance, Rosiglitazone, Metformin/Pioglitazone, Oseni, ActosPlus Met, Alogliptin/pioglitazone, Glimepiride/Pioglitazone, Avandaryl, Glimepiride/Rosiglitazone, Duetact

Diabetes Drug May Help Prevent Second Stroke: Study

Posted 18 Feb 2016 by Drugs.com

WEDNESDAY, Feb. 17, 2016 – The diabetes drug Actos (pioglitazone) appears to protect people who've already had a stroke from suffering a second stroke, a new study finds. Along with standard treatment after a stroke – including blood thinners, and blood pressure and cholesterol medication – the addition of Actos reduced the odds of another stroke by 24 percent compared to a placebo, the researchers said. "Actos represents a new option for patients who have had a stroke to help prevent a future stroke," said lead researcher Dr. Walter Kernan, a professor of medicine at Yale School of Medicine in New Haven, Conn. For the study, Kernan and colleagues randomly assigned nearly 4,000 patients who had suffered a stroke or a mini-stroke to Actos or a placebo. None of the patients had diabetes but they did have evidence of insulin resistance, putting them at risk for the blood-sugar disease. ... Read more

Related support groups: Diabetes, Type 2, Insulin, Ischemic Stroke, Transient Ischemic Attack, Actos, Pioglitazone, Diabetes Mellitus, Ischemic Stroke - Prophylaxis, ActoPlus Met, Intracranial Hemorrhage, Metformin/Pioglitazone, Oseni, Glimepiride/Pioglitazone, ActosPlus Met, Alogliptin/pioglitazone, Duetact

New Diabetes Cases Among Americans Drop for First Time in Decades: CDC

Posted 1 Dec 2015 by Drugs.com

TUESDAY, Dec. 1, 2015 – In a sign that Americans may finally be turning the corner in the fight against diabetes – and possibly obesity – federal health statistics released Tuesday show that the number of new cases of diabetes has dropped for the first time in decades. The decline wasn't sudden or dramatic. But, the number of new diabetes cases went from 1.7 million in 2009 to 1.4 million in 2014, according to the U.S. Centers for Disease Control and Prevention. "It seems pretty clear that incidence rates have now actually started to drop. Initially it was a little surprising because I had become so used to seeing increases everywhere we looked," CDC researcher Edward Gregg told The New York Times. The proportion of Americans with diabetes is still twice what it was in the early 1990s. And not every racial group has made strides against the blood sugar disease, which is often ... Read more

Related support groups: Diabetes, Type 2, Obesity, Metformin, Weight Loss, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Bydureon, Byetta, Janumet, Glyburide, Saxenda, Lantus Solostar, Invokana, Levemir

Type 2 Diabetes Drug Helps Some With Chronic Depression: Study

Posted 18 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 18, 2015 – A new small study is adding evidence to the theory that insulin resistance may play a leading role in some people's depression. The study found that a medication normally used to boost insulin sensitivity in people with type 2 diabetes appears to help ease the symptoms of chronic depression. And, the effect was strongest in people who were insulin-resistant but didn't have diabetes, the study found. These findings "add to the neurobiological explanation of what's going on when people are depressed, and it should help de-stigmatize depression. It's a disease of the brain," said the study's lead author, Dr. Natalie Rasgon, a professor of psychiatry and behavioral sciences at Stanford University School of Medicine in California. "Depression is kind of a catch-all term, like the common cold; it can have more than one cause," Rasgon said. "In this study, we saw ... Read more

Related support groups: Depression, Diabetes, Type 2, Major Depressive Disorder, Postpartum Depression, Insulin Resistance, Actos, Dysthymia, Seasonal Affective Disorder, Pioglitazone, ActoPlus Met, Depressive Psychosis, Metformin/Pioglitazone, Oseni, ActosPlus Met, Glimepiride/Pioglitazone, Alogliptin/pioglitazone, Duetact

Too Many Seniors With Diabetes Are Overtreated, Study Suggests

Posted 29 Oct 2015 by Drugs.com

THURSDAY, Oct. 29, 2015 – When it comes to treating seniors with diabetes, new research suggests that doctors often don't cut back on medications, even when treatment goals are surpassed. The study found that when people had potentially dangerous low blood sugar levels, just 27 percent had their medicines decreased. And when blood pressure treatments lowered blood pressure levels too much, just 19 percent saw a reduction in their medications. "As people get older, the risks of overtreating become greater, and the benefits become shorter. We have to start emphasizing that more isn't always better," said study author Dr. Jeremy Sussman, an assistant professor of internal medicine at the University of Michigan in Ann Arbor and a primary care doctor at the Ann Arbor VA System. The findings were published online Oct. 26 in the journal JAMA Internal Medicine. Practice guidelines generally ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Bydureon, Byetta, Janumet, Saxenda, Glyburide, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

How to Dispose of Unused or Expired Prescription Drugs

Posted 25 Sep 2015 by Drugs.com

FRIDAY, Sept. 25, 2015 – Many people hold on to extra prescription drugs, but saving old medications is unwise, a pharmacist warns. "Medications that are expired have passed their half-life, which leads to them being ineffective," said Kimberly Cimarelli, pharmacy manager at Penn State Milton S. Hershey Medical Center, in Hershey, Pa. Expired medications can even be dangerous, the U.S. Food and Drug Administration says. Their chemical composition can change and, over time, expired drugs may become less effective or potentially harmful. Getting rid of old, unused medications can also help ensure children don't accidentally get their hands on them. Having fewer medications at home can also help prevent mix-ups, the experts pointed out. "Older people who may be easily confused could take the wrong medication because the unwanted or expired medication wasn't disposed of," Officer Rebecca ... Read more

Related support groups: Oxycodone, Hydrocodone, Methadone, Tramadol, OxyContin, Fentanyl, Morphine, Codeine, Metoprolol, Tylenol, Opana, Ibuprofen, Subutex, Naproxen, Atenolol, Dilaudid, Meloxicam, Acetaminophen, Opana ER, Diclofenac

Tight Control of Type 2 Diabetes May Help Prevent Dementia

Posted 15 Sep 2015 by Drugs.com

TUESDAY, Sept. 15, 2015 – Keeping blood sugar levels in check may have a protective effect against dementia in people who have type 2 diabetes, new Swedish research suggests. "The positive association between [average blood sugar levels] and risk of dementia in fairly young patients with type 2 diabetes indicates a potential for prevention of dementia with improved blood sugar control," study author Dr. Aidin Rawshani, from the National Diabetes Register and Institute of Medicine in Gothenburg, Sweden, and colleagues wrote. However, the study wasn't able to definitively prove a cause-and-effect relationship between blood sugar levels and dementia; it was only able to show an association between these factors. The study included almost 350,000 people with type 2 diabetes. They were all registered in the Swedish National Diabetes Registry between January 2004 and December 2012. They had ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Dementia, Glucophage, Novolog, Alzheimer's Disease, Glipizide, Humalog, Janumet, Glyburide, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride, Amaryl, Novolin R, Pioglitazone

Could Common Diabetes Drugs Help Fight Leukemia?

Posted 2 Sep 2015 by Drugs.com

WEDNESDAY, Sept. 2, 2015 – Common diabetes drugs might help eradicate drug-resistant cancer cells in a certain form of leukemia when added to standard treatment, a small new study suggests. Researchers found that patients with chronic myeloid leukemia (CML) who received a glitazone – a class of drug for type 2 diabetes – along with the standard CML drug imatinib remained disease-free for up to nearly five years. Imatinib, known commercially as Gleevec, boasts an impressive track record in controlling chronic myeloid leukemia and allowing patients to lead virtually normal lives. But despite its effectiveness, dormant, drug-resistant leukemic cells typically lay in wait in bone marrow. They can later transform into highly aggressive cells. "Gleevec can control the disease but never get rid of the source of the disease," said Lee Greenberger, chief scientific officer for the Leukemia & ... Read more

Related support groups: Chronic Myelogenous Leukemia (CML), Gleevec, Actos, Pioglitazone, Avandia, ActoPlus Met, Imatinib, Avandamet, Rosiglitazone, Metformin/Pioglitazone, Oseni, Alogliptin/pioglitazone, Glimepiride/Pioglitazone, ActosPlus Met, Avandaryl, Metformin/Rosiglitazone, Duetact, Glimepiride/Rosiglitazone

FDA Warns of Joint Pain Tied to Common Type 2 Diabetes Drugs

Posted 31 Aug 2015 by Drugs.com

FRIDAY, Aug. 28, 2015 – Use of a class of widely prescribed medications for type 2 diabetes is tied to severe joint pain in some patients, the U.S. Food and Drug Administration warned on Friday. The drugs – sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta) and alogliptin (Nesina) – come from a newer class of medications called DPP-4 inhibitors. The drugs can be taken alone or used in conjunction with other diabetes drugs, such as metformin. DPP-4 inhibitors help fight type 2 diabetes by boosting the amount of insulin the body produces after each meal, when blood sugar levels are typically high. However, in a statement, the FDA said the medications "may cause joint pain that can be severe and disabling," and the agency "has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class." The FDA stressed that patients who take ... Read more

Related support groups: Diabetes, Type 2, Metformin, Januvia, Glucophage, Janumet, Pre-Diabetes, Onglyza, Diabetes Mellitus, Tradjenta, Glucophage XR, ActoPlus Met, Sitagliptin, Glumetza, Glyburide/Metformin, Janumet XR, Jentadueto, Avandamet, Glyxambi, Glucovance, Metformin/Pioglitazone

FDA Medwatch Alert: DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain

Posted 28 Aug 2015 by Drugs.com

ISSUE: The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. FDA has added a new Warning and Precaution about this risk to the labels of all medicines in this drug class, called dipeptidyl peptidase-4 (DPP-4) inhibitors. See the Drug Safety Communication for a complete list of all FDA-approved DPP-4 inhibitors. BACKGROUND: DPP-4 inhibitors are used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. When untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. These medicines are available as single-ingredient products and in combination with other diabetes medicines such as metformin. RECOMMENDATION: Patients should not stop taking their DPP-4 ... Read more

Related support groups: Diabetes, Type 2, Januvia, Janumet, Onglyza, Tradjenta, Sitagliptin, Janumet XR, Jentadueto, Glyxambi, Linagliptin, Nesina, Oseni, Saxagliptin, Kombiglyze XR, Alogliptin, Alogliptin/pioglitazone, Kazano, Metformin/Sitagliptin, Alogliptin/metformin, Juvisync

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Related Drug Support Groups

Oseni

Alogliptin / pioglitazone Patient Information at Drugs.com